RT Journal Article
SR Electronic
T1 Point-of-care lung ultrasound predicts severe disease and death due to COVID-19: a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.30.21268558
DO 10.1101/2021.12.30.21268558
A1 Blair, Paul W.
A1 Siddharthan, Trishul
A1 Liu, Gigi
A1 Bai, Jiawei
A1 East, Joshua
A1 Herrera, Phabiola
A1 Anova, Lalaine
A1 Mahadevan, Varun
A1 Hossen, Shakir
A1 Seo, Stefanie
A1 Sonuga, Olamide
A1 Lawrence, Joshua
A1 Peters, Jillian
A1 Cox, Andrea
A1 Manabe, Yukari C.
A1 Fenstermacher, Katherine
A1 Shea, Sophia
A1 Rothman, Richard E.
A1 Hansoti, Bhakti
A1 Sauer, Lauren
A1 Crainiceanu, Ciprian
A1 Clark, Danielle V.
YR 2022
UL http://medrxiv.org/content/early/2022/01/01/2021.12.30.21268558.abstract
AB Objective The clinical utility of point-of-care lung ultrasound (LUS) for disease severity triage of hospitalized patients with COVID-19 is unclear.Design Prospective cohort studySetting A large tertiary care center in Maryland, USA between April 2020 to September 2021.Patients Hospitalized adults (≥18 years of age) with positive SARS-CoV-2 RT-PCR results.Interventions None.Measurements and Main Results All patients were scanned using a standardized protocol including 12 lung zones and followed to determine clinical outcomes until hospital discharge and vital status at 28-days. Ultrasounds were independently reviewed for lung and pleural line artifacts and abnormalities, and the mean Lung Ultrasound Score (ranging from 0 to 3) across lung zones (mLUSS) was determined. The primary outcome was time to ICU-level care, defined as high flow oxygen, noninvasive, or mechanical ventilation, within 28-days of the initial ultrasound. Cox proportional hazards regression models adjusted for age and sex were fit for mLUSS and each ultrasound covariate. A total of 264 participants were enrolled in the study; the median age was 59 years and 114 (43.2) % of participants were female. The median mLUSS was 1 (interquartile range: 0.5 to 1.3). Following enrollment, 29 (11.0%) participants went on to require ICU-level care and 14 (5.3%) subsequently died by 28 days. Each increase in mLUSS at enrollment was associated with disease progression to ICU-level care (aHR = 3.63; 95% CI: 1.23 to 10.65) and 28-day mortality (aHR = 4.50; 95% CI: 1.52 to 13.31). Pleural line abnormalities were independently associated with disease progression to ICU-level care (aHR = 18.86; CI: 1.57 to 226.09).Conclusions Participants with a mLUSS ≥1 or pleural line changes on LUS had an increased likelihood of subsequent requirement of high flow oxygen or greater. LUS is a promising tool for assessing risk of COVID-19 progression at the bedside.Competing Interest StatementY.C.M. receives research funding from Becton Dickinson, Quanterix, and Hologic and receives funding support to Johns Hopkins University from miDiagnostics.Funding StatementThis study was supported by Joint Program Executive Office (JPEO-EB) W911QY-20-9-0004 (2020 OTA) and the Johns Hopkins University School of Medicine COVID-19 Research Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This protocol was approved by the Johns Hopkins University Institutional Review Board (IRB00245545).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.